Podcast, Interview
a16z Podcast | Shifting Risk Mindsets, From Tech to Bio
- New technologies face adoption hurdles with partners and media accustomed to traditional workflows, requiring effective translation of novelty.
- Securing upfront payments and "biobuck-like deals" represents a distinct challenge compared to early proof-of-concept transactions.
- Pharma and biotech entities are expected to reposition themselves as "data science companies" rather than traditional biotech firms.
- Startups risk "death by a thousand pilots" due to long validation timelines and the temptation to initiate projects with early-stage work.
- Pilot engagements with large corporations frequently suffer from scope and timeline creep, often resulting in payments delayed by factors of two while costs double.
- Many entities fail because they operate initially as service providers selling pilots without achieving sustainable economics or transitioning to in-house asset development.
- Bio companies must advance assets closer to clinical stages, as significant value is not realized until a drug candidate enters the clinic.
- Selectivity in pilot partners is critical to avoid "free sampling" from organizations that lack fundamental belief in the technology.
- Platforms solely focused on identifying novel targets struggle to capture value because pharma companies already possess abundant targets and view them as free.
- Companies capable of predicting Phase III trial failures will capture substantial value.
- Founders attempting to design drugs without expertise face a dangerous trajectory.
- A common historical progression involves starting with early-stage deals and hoping to eventually develop drugs and capture downstream economics.
- Business development serves as a strategic advantage to bridge the "fatal chasm" for companies struggling with early-stage pharma deals.
- Deal structures must prevent full encumbrance of the platform to preserve future independence.
- Successful production of a specific drug asset often triggers an immediate shift of focus to that single program, potentially neglecting the broader platform due to fixed resource pools.
- Structuring deals via separate LLCs allows parent companies to replicate success by bringing in new investors for specific assets while the parent funds the platform.
- The entire value of unvalidated platforms may depend on the success of a single asset that validates the platform's efficacy.
- Failure of a first asset risks discarding a good platform or validating a bad platform, whereas "engineering-like" platforms are viewed as more generalizable and fundamental.
- The optimal structures for different platform types remain uncertain and will be determined over time.
- Venture communities and entrepreneurs will require time to become socialized to LLC structures.
- For diagnostics, reimbursement strategies should be prioritized before addressing FDA or CLIA regulations.
- Focusing on reimbursement and go-to-market early leads to better long-term outcomes.
- Biology-engineered companies can apply capabilities across different indications rather than being limited to bespoke processes.
- Broad-based reimbursement for early-stage screening diagnostics may not yield a positive ROI for payers due to patient turnover.
- Backloaded returns of five to ten years necessitate changes in payment mechanisms and financial incentives.
- Proposals are being developed to create financial mechanisms where insurance companies can establish incentives.
- Pilot projects with insurers or payers offer potential for therapeutic developers to demonstrate ROI.
- Proof-of-concept challenges persist for broader biology companies not focused on human health.
- Companies engineering new bacteria or similar technologies should productize as instruments, targeting the high end of the market initially.
- Market access is expected to expand as technology performance improves and costs decrease.
- Entrepreneurs should design simple experiments with high predictability as near-term proof points.
- Over time, system complexity, throughput, quality, and cost will evolve.
- Products should be designed for early adopter POCs with a clear path to the end of the market.
- Entrepreneurs must identify near-term "killer experiments" to validate or kill ideas within six to twelve months.
- Core hypotheses must be validated through repeated experimentation before proceeding.
- Investors are warned against delaying the execution of killer experiments.
- Tech investors may be less equipped to handle science risk compared to biotech investors.
- Hybrid companies may benefit from a syndicate combining traditional bio and tech investors to bridge knowledge gaps.
- Investor syndicate composition may shift toward traditional bio or tech as the company matures, eventually reaching late-stage investors.
- Entrepreneurs must anticipate the requirements of the next funding round regarding metrics, milestones, and investor bases.
- Entrepreneurs should achieve fluency in either tech or bio languages while maintaining functional understanding of the other.
- Companies must establish a common set of languages and ideas to facilitate communication with potential bioinvestors.